Pembrolizumab-Associated Hypothyroidism: Case Report and Review of Literature

Authors

Niranjan Tachamo, Internal Medicine Department, Reading Health System, Sixth Avenue and Spruce Street, Wyomissing, PA 19611, USA
Saroj Lohani, Internal Medicine Department, Reading Health System, Sixth Avenue and Spruce Street, Wyomissing, PA 19611, USA
Salik Nazir, Internal Medicine Department, Reading Health System, Sixth Avenue and Spruce Street, Wyomissing, PA 19611, USAFollow
Rishikesh Joshi, Tribhuvan University, Kathmandu, Nepal
Mrunalini Deshmukh, Tribhuvan University, Kathmandu, Nepal

Document Type

Article

Publication Date

6-27-2017

Abstract

Pembrolizumab is a Programmed Death 1 (PD-1) inhibitor used to treat advanced malignant melanoma and metastatic non-small cell lung cancer. It causes various endocrinological side effects including immune mediated thyroiditis. Thyroiditis caused by Pembrolizumab can mimic other immune mediated thyroiditis like Hashimoto thyroiditis and Grave’s disease.

Publication Title

Journal of Internal Medicine and Patient Care

Volume

1

Issue

1

First Page

107

Last Page

107

Recommended Citation

Tachamo, N., Lohani, S., Nazir, S., Joshi, R., & Deshmukh, M. (2017). Pembrolizumab-Associated Hypothyroidism: Case Report and Review of Literature. Journal of Internal Medicine and Patient Care, 1 (1), 107-107. Retrieved from https://scholarcommons.towerhealth.org/gme_int_med_resident_program_read/140